US 11407997
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
granted A61KA61K31/7088A61P
Quick answer
US patent 11407997 (Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders) held by CRISPR THERAPEUTICS AG expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/7088, A61P, A61P3/00